Compare Costco Wholesale Corporation (COST) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Novo Nordisk A/S — how do they compare? Costco Wholesale Corporation trades at $924.05 (market cap $408.78B), while Novo Nordisk A/S trades at $50.44 (market cap $214.94B). The key difference: Costco Wholesale Corporation is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| COST | NVO | |
|---|---|---|
Market Cap | $408.78B | $214.94B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $71.70 |
52-Week Low | $849.63 | $35.29 |
Enterprise Value | $396.92B | $233.91B |
Dividend Yield | 0.64% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $923.9, down 0.27% with bearish technical signals but strong fundamentals. The stock shows consistent revenue growth, reaching $275.24B in 2025 with net income of $8.10B. Recent March sales surged 11.3% year-over-year to $28.41B, indicating robust business momentum. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,120 price target, though valuation metrics appear elevated with P/E at 46.37.
The investment case balances premium valuation against exceptional operational execution. Membership fee increases and expanding warehouse network drive profitability, but high P/E ratio requires sustained growth. Key risks include competitive pressure and economic sensitivity, while institutional accumulation supports long-term confidence.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
